The Pharmaletter

One To Watch

LinkGevity

An AI-driven drug discovery company focused on age-related diseases and longevity.

The company’s flagship therapeutic is a first-in-class Anti-Necrotic, which has earned a Horizon Europe grant from the European Union alongside UK government funding. LinkGevity was also selected as one of only 12 companies globally for the NASA/Microsoft Space-Health Program, due to the Anti-Necrotic’s potential in preventing accelerated aging and tissue degeneration in astronauts.

The company plans to initiate a flagship clinical trial later in 2025, on the treatment of tissue degeneration in the kidney and associated aging and disease – the ninth leading cause of death in the world today according to the WHO - and broadening from there to other age-related indications.

Want to Update your Company's Profile?


Latest LinkGevity News

More LinkGevity news >